<bold> COMBINATION OF TUMOR TREATING FIELDS </bold>(TTFIELDS) WITH LOMUSTINE (CCNU) AND TEMOZOLOMIDE (TMZ) IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) PATIENTS - A BI-CENTRIC ANALYSIS

被引：0
作者：
Lazaridis, Lazaros [1 ]
Schaefer, Niklas [2 ]
Schmidt, Teresa [3 ]
Weller, Johannes [2 ]
Tzaridis, Theophilos-Dimitrios [2 ]
Scheffler, Bjoern [4 ]
Pierscianek, Daniela [5 ]
Kleinschnitz, Christoph [6 ]
Stuschke, Martin [7 ]
Sure, Ulrich [5 ]
Herrlinger, Ulrich [2 ]
Kebir, Sied [1 ]
Glas, Martin [3 ]
机构：
[1] Univ Hosp Essen, Div Clin Neurooncol, Dept Neurol, Essen, Germany
[2] Univ Bonn, Div Clin Neurooncol, Dept Neurol, Med Ctr, Bonn, Germany
[3] Univ Duisburg Essen, Univ Hosp Essen, Div Clin Neurooncol, Dept Neurol, Essen, Germany
[4] Partner Site Univ Hosp Essen, German Canc Consortium DKTK, West German Canc Ctr WTZ, DKFZ,Div Translat Neurooncol, Essen, Germany
[5] Univ Duisburg Essen, Univ Hosp Essen, Dept Neurosurg, Essen, Germany
[6] Univ Duisburg Essen, Univ Hosp Essen, Dept Neurol, Essen, Germany
[7] Univ Duisburg Essen, Univ Hosp Essen, Dept Radiotherapy, Essen, Germany
来源：
NEURO-ONCOLOGY | 2019年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
RARE-39
引用
收藏
页码：229 / 230
页数：2
相关论文
共 50 条
  • [41] Safety and efficacy of tumor treating fields (TTFields) prior and concomitant to radiotherapy in patients with newly diagnosed glioblastoma: Results from PriCoTTF
    Kebir, Seid
    Lazaridis, Lazaros
    Schmidt, Teresa
    Oster, Christoph
    Proescholdt, Martin
    Hau, Peter
    Grosu, Anca L.
    Krex, Dietmar
    Sure, Ulrich
    Scheffler, Bjoern
    Kleinschnitz, Christoph
    Ttgen, Christoph Po Spacing Diaeresis
    Stuschke, Martin
    Glas, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [42] Tumor treating fields treatment for patients with newly diagnosed glioblastoma: A cost-effectiveness analysis
    Guzauskas, Gregory F.
    Pollom, Erqi L.
    Stieber, Volker W.
    Wang, Bruce C.
    Garrison, Lou
    CANCER RESEARCH, 2018, 78 (13)
  • [43] SPARE TRIAL: SCALP-SPARING RADIATION WITH CONCURRENT TEMOZOLOMIDE AND TUMOR TREATING FIELDS FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
    Miller, Ryan
    Song, Andrew
    Ali, Ayesha S.
    Bar-Ad, Voichita
    Martinez, L.
    Glass, Jon
    Alnahhas, Iyad
    Andrews, David
    Judy, Kevin
    Evans, James
    Farrell, Christopher
    Werner-Wasik, Maria
    Chervoneva, Inna
    Ly, May
    Palmer, Joshua
    Liu, Haisong
    Shi, Wenyin
    NEURO-ONCOLOGY, 2021, 23 : 43 - 44
  • [44] FINAL ANALYSIS OF ACT III: A PHASE II TRIAL OF PF-04948568 (CDX-110) IN COMBINATION WITH TEMOZOLOMIDE (TMZ) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
    Lai, Rose K.
    Recht, Lawrence D.
    Reardon, David A.
    Paleologos, Nina
    Groves, Morris
    Rosenfeld, Myrna R.
    Meech, Sandra
    Davis, Tom
    Pavlov, Dmitri
    Marshall, Margaret A.
    Sampson, John
    NEURO-ONCOLOGY, 2010, 12 : 76 - 77
  • [45] NCCTG phase I trial of temsirolimus (CCI-779) and temozolomide (TMZ) in combination with radiation therapy (RT) in newly diagnosed glioblastoma multiforme (GBM) patients
    Sarkaria, J. N.
    Galanis, E.
    Wu, W.
    Giannini, C.
    Jaeckle, K. A.
    Doyle, L.
    Uhm, J.
    Brown, P.
    Dietz, A. B.
    Buckner, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [46] EF-32 (TRIDENT): A pivotal randomized trial of radiation therapy concomitant with temozolomide plus /- Tumor Treating Fields (TTFields) in newly diagnosed glioblastoma.
    Shi, Wenyin
    Kleinberg, Lawrence
    Jeyapalan, Suriya A.
    Goldlust, Samuel A.
    Nagpal, Seema
    Combs, Stephanie E.
    Roberge, David
    Nishigawa, Ryo
    Grossman, Rachel
    Glas, Martin
    CANCER RESEARCH, 2021, 81 (13)
  • [47] TIME TO FUNCTIONAL AND COGNITIVE DECLINE IN A PHASE 3 TRIAL OF TUMOR TREATING FIELDS WITH TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
    Nicholas, Garth A.
    Hirte, Holger
    Easaw, Jacob
    Muanza, Thierry
    Roberge, David
    Mathieu, David
    Pitz, Marshall
    NEURO-ONCOLOGY, 2017, 19 : 138 - 138
  • [48] CONCURRENT CHEMORADIATION AND TUMOR TREATING FIELDS (TTFIELDS, 200 KHZ) FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MAY INCREASE THE RATE OF DISTANT RECURRENCE
    Ali, Ayesha S.
    Niazi, Muneeb
    Bar-Ad, Voichita
    Werner-Wasik, Maria
    Andrews, David
    Farrell, Christopher
    Evans, James
    Judy, Kevin
    Glass, Jon
    Martinez, Nina L.
    Alnahhas, Iyad
    Chervoneva, Inna
    Shi, Wenyin
    NEURO-ONCOLOGY, 2021, 23 : 63 - 63
  • [49] PHASE III TRIAL OF CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA PATIENTS: THE CeTeg/NOA-09 trial
    Herrlinger, Ulrich
    Tzaridis, Theophilos
    Mack, Frederic
    Steinbach, Joachim
    Schlegel, Uwe
    Sabel, Michael
    Hau, Peter
    Kortman, Rolf-Dieter
    Krex, Dietmar
    Grauer, Oliver
    Goldbrunner, Roland
    Schnell, Oliver
    Baehr, Oliver
    Uhl, Martin
    Tabatabai, Ghazaleh
    Ringel, Florian
    Schmidt-Graf, Friederike
    Brehmer, Stefanie
    Weyerbrock, Astrid
    Bullinger, Lars
    Vajkoczy, Peter
    Vatter, Hartmut
    Schaefer, Niklas
    Kebir, Sied
    Weller, Johannes
    Stummer, Walter
    Simon, Matthias
    Keil, Vera
    Nelles, Michael
    Fimmers, Rolf
    Pietsch, Torsten
    Hattingen, Elke
    Coch, Christoph
    Glas, Martin
    NEURO-ONCOLOGY, 2017, 19 : 13 - 14
  • [50] Concurrent Chemoradiation and Tumor Treating Fields (TTFields, 200 kHz) for Patients With Newly Diagnosed Glioblastoma May Increase the Rate of Distant Recurrence
    Ali, A.
    Niazi, M. Z. K.
    Bar-Ad, V.
    Werner-Wasik, M.
    Andrews, D. W.
    Farrell, C.
    Evans, J.
    Judy, K.
    Glass, J.
    Martinez, N.
    Alnahhas, I.
    Chervoneva, I.
    Shi, W.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E596 - E596
12345